Biologics, Biosimilars
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,781
NCT03013504
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
Phase: Phase 3
Role: Lead Sponsor
Start: Feb 19, 2018
Completion: Jan 13, 2022
NCT03390673
To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects
Phase: Phase 1
Start: Sep 19, 2018
Completion: Mar 13, 2019
NCT03776240
A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects
Start: Apr 1, 2019
Completion: Aug 19, 2019
NCT03390686
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
Start: Nov 15, 2019
Completion: Dec 31, 2025
NCT05108259
To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects
Start: Mar 30, 2022
Completion: May 31, 2026
NCT05141149
First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer
Phase: Phase 1/2
Start: Jun 5, 2023
Completion: Dec 31, 2026
Loading map...